Anwar Sumadi Lukman, Raharjo Clarista Adelia, Herviastuti Rahma, Dwianingsih Ery Kus, Setyoheriyanto Didik, Avanti Widya Surya, Choridah Lina, Harahap Wirsma Arif, Aryandono Teguh, Wulaningsih Wahyu
Division of Surgical Oncology-Department of Surgery, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada (Dr. Sardjito Hospital), Jalan Kesehatan No 1, Yogyakarta, 55281, Indonesia.
PILAR Research and Education, 20 Station Road, Cambridge, CB1 2JD, UK.
BMC Womens Health. 2019 Feb 6;19(1):28. doi: 10.1186/s12905-019-0724-3.
Breast cancer diagnosed at a young age is often associated with aggressive biology, advanced stage, and unfavorable prognosis. The median age of breast cancer diagnosis in Indonesia is younger (48 vs. 68 years-old in Europe) with a relatively higher proportion of patients younger than 40 years old. Although prognosis and outcome of young breast cancer are well studied in developed nations, research evaluating biological characteristics, delivered treatment, and clinical outcomes is very limited in Indonesia.
We analyzed all breast cancer patients who underwent surgery at Dr. Sardjito Hospital, Indonesia, in 2012-2017. Details of pathology profiles, treatment administrated, and outcomes, as well as reproductive factors among patients younger than 40 years old, were collected and analyzed. Kaplan-Meier curve was used to assess conditional survival based on baseline characteristics.
From the total of 1259 breast cancer patients (median age 51 years), 144 (11.4%) were younger than 40 years old (median age 37 years). Of these young patients, 19 (13.2%) were bilateral and 92 (64%) were diagnosed in advanced stages (stages IIIA-C and IV). Median tumor diameter was 5.5 cm and nodal infiltration was present in 73%. Distant metastasis was found in 16% at the time of diagnosis. Moderate and poor differentiation of tumor were 20.8 and 78.5%, respectively, and lymphovascular invasion was found in 90.3%. Around 40% were hormone receptor-positive, 30.6% human epidermal growth factor receptor 2 positive, and 38.2% triple negative. Patients underwent radical surgery in 121 cases (84%) and breast conserving surgery in 7 cases (4.9%). Adjuvant chemotherapy was administrated in 68% and hormonal therapy in 34%. Progression-free survival was significantly shorter in patients with advanced stage, skin and chest wall involvement (T4), positive lymph node infiltration, positive hormonal receptor, and triple negative subtype (log-rank Mantel-Cox tests, p < 0.05).
We found a high frequency of young breast cancer with biologically more aggressive tumors, late diagnosis, frequent relapse, and poor prognosis. Further actions to improve clinical management and meet psychosocial needs in young breast cancer patients are warranted.
年轻时被诊断出的乳腺癌通常与侵袭性生物学行为、晚期阶段及不良预后相关。印度尼西亚乳腺癌诊断的中位年龄较年轻(48岁,而欧洲为68岁),40岁以下患者的比例相对较高。尽管在发达国家对年轻乳腺癌的预后和结局已有充分研究,但在印度尼西亚,评估生物学特征、所接受治疗及临床结局的研究非常有限。
我们分析了2012年至2017年在印度尼西亚萨迪托博士医院接受手术的所有乳腺癌患者。收集并分析了病理特征细节、所给予的治疗及结局,以及40岁以下患者的生殖因素。采用Kaplan-Meier曲线根据基线特征评估条件生存情况。
在总共1259例乳腺癌患者(中位年龄51岁)中,144例(11.4%)年龄小于40岁(中位年龄37岁)。在这些年轻患者中,19例(13.2%)为双侧发病,92例(64%)诊断为晚期(IIIA-C期和IV期)。肿瘤中位直径为5.5厘米,73%存在淋巴结浸润。诊断时发现16%有远处转移。肿瘤中分化和低分化分别为20.8%和78.5%,90.3%存在脉管浸润。约40%为激素受体阳性,30.6%人表皮生长因子受体2阳性,38.2%为三阴性。121例患者(84%)接受了根治性手术,7例患者(4.9%)接受了保乳手术。68%的患者接受了辅助化疗,34%接受了激素治疗。晚期、皮肤及胸壁受累(T4)、阳性淋巴结浸润、阳性激素受体及三阴性亚型患者的无进展生存期明显较短(对数秩Mantel-Cox检验,p<0.05)。
我们发现年轻乳腺癌的发病率较高,其肿瘤生物学行为更具侵袭性,诊断较晚,复发频繁,预后较差。有必要采取进一步行动来改善年轻乳腺癌患者的临床管理并满足其心理社会需求。